Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy

Not Applicable

Completed

• Conditions: Head and Neck Cancer
• Interventions: Radiation: Intensity-modulated Radiotherapy

• Registration Number: NCT01955239
• Lead Sponsor: University Medical Center Groningen

Brief Summary

Rationale:

Radiation-induced parotid gland dysfunction, often leading to xerostomia is the most-frequently occurring side-effect with a major impact on patient-reported quality of life after radiotherapy for head and neck cancer (HNC). Therefore, treatments for HNC are currently optimized to minimize the mean dose to the parotid glands. Though this resulted in a significant reduction of toxicity, 30%-40% of the patients still develop sustained parotid gland dysfunction and xerostomia.

However, in animal studies the investigators found that the dose to the sub-volume of the gland containing the parotid gland stem cells is a better predictor for dysfunction than the mean dose to the whole gland. Subsequently, this finding was confirmed in a retrospective analysis in patients. Therefore, a reduction of dose specifically in this sub-volume of the parotid glands of patients is expected to further reduce the risk of parotid gland dysfunction and xerostomia.

Objective:

To test the hypothesis that parotid gland stem cell sparing intensity modulated radiotherapy in HNC patients reduces the risk of parotid gland dysfunction and xerostomia as compared to conventional parotid gland sparing intensity modulated radiotherapy.

Study design:

Double-blind prospective randomized trial (51 patients per arm). Study population: Patients treated for tumours in the head-and-neck region with curative radiotherapy, with or without the addition of chemotherapy or cetuximab.

Intervention: Patients randomized into the experimental arm will receive a treatment in which the radiation dose to the parotid gland is re-distributed to minimize dose to the sub-volume containing the stem cells, while keeping the same mean dose to the parotid gland as a whole.

Main study parameters/endpoints:

Primary endpoint is parotid gland salivary secretion. Secondary endpoints are patient- and physician-rated xerostomia.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2013-09-27
• Study First Submitted QC: 2013-10-04
• Study First Posted: 2013-10-07
• Primary Completion: 2017-05
• Study Completion: 2017-05
• Status Verified: 2017-06
• Last Update Submitted: 2017-06-21
• Last Update Posted: 2017-06-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• Squamous cell carcinoma originating from the mucosa of the head and neck area or nasopharyngeal carcinoma originating from the nasopharynx;
• The radiotherapy includes prophylactic or therapeutic irradiation of both sides of the neck (at least level II to IV);
• Age ≥ 18 years;
• WHO performance 0-2;
• To reduce the uncertainty in the assessment of relative flow after treatment, pre-treatment parotid gland saliva production stimulated with 5% citric acid should exceed >0.1 ml/min

Exclusion Criteria

• Postoperative radiotherapy;
• Previous radiotherapy of the head and neck region (re-irradiation);
• Unilateral radiotherapy;
• Primary salivary gland tumours

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Standard IMRT	Intensity-modulated Radiotherapy	Standard IMRT in which the mean dose to both whole parotid glands is minimized.
Stem-cell Sparing IMRT	Intensity-modulated Radiotherapy	Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized

Primary Outcome Measures

Name	Time	Method
Salivary flow	12 months after radiotherapy

Secondary Outcome Measures

Name	Time	Method
Patient-rated Xerostomia	12 months after radiotherapy

Trial Locations

Locations (1)

University Medical Center Groningen; 🇳🇱 Groningen, Netherlands